At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01167 JACOBIO-B
Closed 12-22 16:08:10
7.830
-1.230
-13.58%
High8.800Low7.500Vol24.67M
Open8.800D1 Closing9.060Amplitude14.35%
Mkt Cap6.16BTradable Cap6.16BTotal Shares787.00M
T/O196.13MT/O Rate3.13%Tradable Shares787.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Stock Track | JACOBIO-B Plummets 12.58% Intraday After Selling JAB-23E73 License to AstraZeneca
Stock Track  ·  10:56
Stock Track | JACOBIO-B Plummets 12.58% Intraday After Selling JAB-23E73 License to AstraZeneca
AstraZeneca Joins the Fray: The Battle Over Pan-KRAS Inhibitor Technology Begins to Shift
Stock News  ·  08:50
AstraZeneca Joins the Fray: The Battle Over Pan-KRAS Inhibitor Technology Begins to Shift
China Shenhua (01088) Launches 100 Billion Yuan Asset Restructuring; COMEX Silver Hits Record High
Stock News  ·  07:20
China Shenhua (01088) Launches 100 Billion Yuan Asset Restructuring; COMEX Silver Hits Record High
Jacobio Pharma Enters Global Exclusive License Agreement With AstraZeneca for Pan-Kras Inhibitor Jab-23E73
THOMSON REUTERS  ·  12-21 20:15
Jacobio Pharma Enters Global Exclusive License Agreement With AstraZeneca for Pan-Kras Inhibitor Jab-23E73
JACOBIO-B (01167) Subsidiary Enters Licensing Agreement with AstraZeneca to Develop and Commercialize Pan-KRAS Inhibitor JAB-23E73
Stock News  ·  12-21 20:01
JACOBIO-B (01167) Subsidiary Enters Licensing Agreement with AstraZeneca to Develop and Commercialize Pan-KRAS Inhibitor JAB-23E73
Jacobio Pharmaceuticals Partners with AstraZeneca on Pan-KRAS Inhibitor JAB-23E73
Reuters  ·  12-21 19:55
Jacobio Pharmaceuticals Partners with AstraZeneca on Pan-KRAS Inhibitor JAB-23E73
HK Movers | Biomedical Stocks Jump With Xuanzhu Biopharmaceutical up 22%
Tiger Newspress  ·  12-12
HK Movers | Biomedical Stocks Jump With Xuanzhu Biopharmaceutical up 22%
HK Stock Movement | JACOBIO-B (01167) Surges Over 11% Again After Receiving RMB125M Initial Payment from Oceanpine Capital
Stock News  ·  12-10
HK Stock Movement | JACOBIO-B (01167) Surges Over 11% Again After Receiving RMB125M Initial Payment from Oceanpine Capital
Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
Simply Wall St.  ·  12-08
Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
HK Stock Movement | JACOBIO-B (01167) Surges Over 6% Intraday as Subsidiary Receives RMB125M Upfront Payment and Combination Therapy Published in The Lancet
Stock News  ·  12-04
HK Stock Movement | JACOBIO-B (01167) Surges Over 6% Intraday as Subsidiary Receives RMB125M Upfront Payment and Combination Therapy Published in The Lancet
Jacobio (01167) Announces November 2025 Share Repurchase Data
Bulletin Express  ·  12-03
Jacobio (01167) Announces November 2025 Share Repurchase Data
Jacobio Pharmaceuticals Unit Receives Upfront Payment From Oceanpine Capital; Shares Lose 3%
MT Newswires Live  ·  12-03
Jacobio Pharmaceuticals Unit Receives Upfront Payment From Oceanpine Capital; Shares Lose 3%
JACOBIO-B (01167) Receives First Payment Under Capital Increase and Equity Transfer Agreements
Stock News  ·  12-02
JACOBIO-B (01167) Receives First Payment Under Capital Increase and Equity Transfer Agreements
Jacobio Unveils Positive Clinical Data for KRAS G12C and SHP2 Inhibitor Combination in The Lancet Respiratory Medicine
Reuters  ·  12-01
Jacobio Unveils Positive Clinical Data for KRAS G12C and SHP2 Inhibitor Combination in The Lancet Respiratory Medicine
Jacobio (1167) Announces Positive Phase I/IIa Results for KRAS G12C + SHP2 Inhibitor Combination
Bulletin Express  ·  12-01
Jacobio (1167) Announces Positive Phase I/IIa Results for KRAS G12C + SHP2 Inhibitor Combination
JACOBIO-B (01167): KRAS G12C and SHP2 Combination Therapy Data Published in The Lancet Respiratory Medicine
Stock News  ·  12-01
JACOBIO-B (01167): KRAS G12C and SHP2 Combination Therapy Data Published in The Lancet Respiratory Medicine
Rock star Growth Puts Jacobio Pharmaceuticals Group (HKG:1167) In A Position To Use Debt
Simply Wall St.  ·  11-26
Rock star Growth Puts Jacobio Pharmaceuticals Group (HKG:1167) In A Position To Use Debt
HK Stock Movement | JACOBIO-B (01167) Rises Over 5% as Pan-KRAS Inhibitor JAB-23E73 Expected to Release Phase 1 Data in H1 2026
Stock News  ·  11-20
HK Stock Movement | JACOBIO-B (01167) Rises Over 5% as Pan-KRAS Inhibitor JAB-23E73 Expected to Release Phase 1 Data in H1 2026
Jacobio Pharmaceuticals Says Andrea Wang-Gillam Appointed As Co-CEO
Reuters  ·  11-20
Jacobio Pharmaceuticals Says Andrea Wang-Gillam Appointed As Co-CEO
Riding the Hong Kong Stock Rally: Bull Market Dawns in the East 2026 – 10th Zhitong Finance Capital Markets Annual Conference Invites You to a Capital Feast
Stock News  ·  11-18
Riding the Hong Kong Stock Rally: Bull Market Dawns in the East 2026 – 10th Zhitong Finance Capital Markets Annual Conference Invites You to a Capital Feast

Introduction

Company Name.
JACOBIO-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Jacobio Pharmaceuticals Group Co Ltd is an investment holding company mainly engaged in the research and development of new drugs at the clinical stage. The Company is primarily responsible for the independent discovery and development of innovative tumor therapies. The Company's main drug development projects include JAB-21822 and JAB-3312 clinical stage allosteric SHP2 inhibitors. The Company mainly operates its businesses in China market.
Issue price:
--